

WEST Search History

DATE: Tuesday, November 29, 2005

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L11	richard.in. and kream.in.	7
<input type="checkbox"/>	L10	18 and L9	4
<input type="checkbox"/>	L9	flexible near hinge	7711
<input type="checkbox"/>	L8	17 and (link or linker or linked)	398
<input type="checkbox"/>	L7	14 and 15 and L6	427
<input type="checkbox"/>	L6	chimera or fusion	239274
<input type="checkbox"/>	L5	opioid	9347
<input type="checkbox"/>	L4	substance adj p	7707
<input type="checkbox"/>	L3	landsman.xa.	96
		<i>DB=USPT; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L2	substance adj p	3388
<input type="checkbox"/>	L1	landsman.xa.	96

END OF SEARCH HISTORY

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 06:34:10 ON 29 NOV 2005

=> file medline biosis caplus
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 06:34:23 ON 29 NOV 2005

FILE 'BIOSIS' ENTERED AT 06:34:23 ON 29 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 06:34:23 ON 29 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> substance adj p
L1 0 SUBSTANCE ADJ P

=> substance p
L2 61912 SUBSTANCE P

=> opioid
L3 129335 OPIOID

=> l2 and l3
L4 2275 L2 AND L3

=> chimera or fusion
L5 518064 CHIMERA OR FUSION

=> l4 and l5
L6 16 L4 AND L5

=> flexible hinge
L7 646 FLEXIBLE HINGE

=> link or linker or linked
L8 914979 LINK OR LINKER OR LINKED

=> l6 and l8
L9 3 L6 AND L8

=> l7 and l9
L10 0 L7 AND L9

=> richard?/au and kream?/au
L11 11 RICHARD?/AU AND KREAM?/AU

=> l6 and 1970-2002/py
L13 10 L6 AND 1970-2002/PY

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14 6 DUP REM L13 (4 DUPLICATES REMOVED)

=> d ti abs so l14 1-6

L14 ANSWER 4 OF 6 MEDLINE on STN DUPLICATE 1
TI Inhibition of morphine tolerance development by a substance
P-opioid peptide chimera.
AB The neuropeptide substance P (SP), apart from its

traditional role in spinal nociceptive processing, is an important regulatory effector of **opioid**-dependent analgesic processes. The present study stems from our original findings indicating that 1) pharmacologically administered SP mediates a strong inhibitory activity on the development of morphine tolerance in rats, and that 2) a novel SP-**opioid** peptide **chimera** YPFFGLM-NH(2), designated ESP7, produces **opioid**-dependent analgesia without tolerance development. To further examine the effects of simultaneous activation of two distinct opposing spinal systems on **opioid** tolerance and the mechanisms underlying chimeric peptide function, a second SP-**opioid chimera** was synthesized. This **chimera**, designated ESP6 (YPFFPLM-NH(2)), contains overlapping domains of endomorphin-2 and SP, respectively. ESP6 is distinguished from ESP7 by a glycine to proline substitution at position 5. Intrathecal administration of morphine sulfate (MS) with ESP6 leads to a prolongation of MS analgesia over a 5-day period. The analgesia produced by ESP6 and MS is **opioid** receptor-dependent, due to the ability of naltrexone to block the analgesic response. Furthermore, when ESP6 and MS are administered with concurrent NK-1 receptor blockade, a decay in analgesic potency similar to that seen with MS alone results. The presence of a proline in ESP6 appears to reduce its conformational flexibility, limit its potency at the micro-**opioid** receptor, and hinder its analgesic effectiveness alone. However, ESP6 represents a novel adjuvant for the maintenance of **opioid** analgesia over time and provides a means to predict the pharmacological properties of a **chimera** from its structure.

SO Journal of pharmacology and experimental therapeutics, (2000 Dec)
295 (3) 1142-8.
Journal code: 0376362. ISSN: 0022-3565.

L14 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
TI Production of peptide or protein as **fusion** proteins
AB A **fusion** protein (markush structure given) containing a carrier protein, ≥ 1 enzyme cleavable peptide sequences as linkers, and desired peptide in tandem repeat (markush structure given). Construction of expression plasmid pMD500R5 encoding a **fusion** protein of protein A-linkers-5 VIP units (vasoactive intestinal polypeptide) was shown. The plasmid was transformed into *Bacillus subtilis* SPL14 for fermentation of the **fusion** protein. Also shown was the preparation of VIP from the **fusion** protein by incubation with basic amino acid-specific protease, blood coagulation factor Xa, and kallikrein.
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

L14 ANSWER 6 OF 6 MEDLINE on STN DUPLICATE 2
TI **Opioid** and neurokinin activities of **substance**
P fragments and their analogs.
AB Newly developed **substance P** (SP) analogs with altered N-terminal sequences which equalize the lipophilicity of the N-terminal and C-terminal elements and of their **fusion** product were examined using i.t. injection in mice. I.t. injection of either the full length analog or the C-terminal hexapeptide (CP) produced biting and scratching behavior similar to that elicited by SP. SPF was approximately 5-fold and CP 14-fold less potent than native SP. The N-terminal peptide (NP) was inactive by itself but inhibited CP-elicited behavior. Naloxone antagonized this action of NP and shifted the SPF dose-response curve 4-fold to the left. However, naloxone had no effect on the action of CP or on the action of any of the native neurokinins. The results are consistent with the hypothesis that N- and C-terminal analogs of SP can have **opioid** and SP-like actions, respectively, in the CNS of rodents. Furthermore, analogs of SP which include at least the terminal tetrapeptide retain neurokinin activity.
SO European journal of pharmacology, (1991 Feb 7) 193 (2) 209-15.
Journal code: 1254354. ISSN: 0014-2999.

=> d his

(FILE 'HOME' ENTERED AT 06:34:10 ON 29 NOV 2005)

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 06:34:23 ON 29 NOV 2005

L1 0 SUBSTANCE ADJ P
L2 61912 SUBSTANCE P
L3 129335 OPIOID
L4 2275 L2 AND L3
L5 518064 CHIMERA OR FUSION
L6 16 L4 AND L5
L7 646 FLEXIBLE HINGE
L8 914979 LINK OR LINKER OR LINKED
L9 3 L6 AND L8
L10 0 L7 AND L9
L11 11 RICHARD?/AU AND KREAM?/AU
L12 1 L9 AND 1970-2002/PY
L13 10 L6 AND 1970-2002/PY
L14 6 DUP REM L13 (4 DUPLICATES REMOVED)

=> logoff